Abstract
Alzheimer disease is characterized as a brain disorder that impairs an individual’s ability of memorizing, thinking, and behavior. The condition is considered as the most common form of dementia, and it is likely to worsen over time; however, it is not a normal part of aging (Abraha et al. 2017). Dementia is associated with loss of memory and other cognitive capabilities of individuals. The individuals suffering from dementia have a comorbid health condition (Bunn et al. 2014). Forgetfulness is the major problem faced by the individuals suffering from Alzheimer, which affects their functionality at home and office. Dementia has been chosen as the most accurate term to describe Alzheimer’s disease (Mace and Rabins 2011). The individual remains confused, misplaces things, gets lost in familiar places, and is also troubled while communicating with peers. The onset of Alzheimer results in the prevention of brain cells to perform well. This condition may lead to disorientation, confusion, intellectual impairment, and memory loss (Bennett et al. 2005).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abraha I, Rimland JM, Trotta FM, Dell’Aquila G, Cruz-Jentoft A, Petrovic M, Cherubini A (2017) Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open 7(3):e012759
Alzheimer’s Association, 2005. Basics of Alzheimer’s disease
Amjad H, Roth DL, Samus QM, Yasar S, Wolff JL (2016) Potentially unsafe activities and living conditions of older adults with dementia. J Am Geriatr Soc 64(6):1223–1232
Ashraf J, Ahmad J, Ali A, Ul-Haq Z (2018) Analyzing the behavior of neuronal pathways in Alzheimer’s using petri net modeling approach. Front Neuroinform 12:26
Austrom MG, Boustani M, LaMantia MA (2018) Ongoing medical management to maximize health and well-being for persons living with dementia. The Gerontologist 58(suppl_1):S48–S57
Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23(4):213–227
Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS (2005) Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64(5):834–841
Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68(2):270–281
Bunn F, Burn AM, Goodman C, Rait G, Norton S, Robinson L, Brayne C (2014) Comorbidity and dementia: a scoping review of the literature. BMC Med 12(1):192
Cacace R, Sleegers K, Van Broeckhoven C (2016) Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement 12(6):733–748
Castello MA, Soriano S (2014) On the origin of Alzheimer’s disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev 13:10–12
De Strooper B, Karran E (2016) The cellular phase of Alzheimer’s disease. Cell 164(4):603–615
Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, Weiner MW (2007) Different regional patterns of cortical thinning in Alzheimer’s disease and frontotemporal dementia. Brain 130(4):1159–1166
ElSharkawy AM (2014) Breast cancer. In: Al-Naggar RA (ed) Principles and practice of cancer prevention and control. OMICS Group eBooks, Foster City
Fazio S, Pace D, Kallmyer B, Pike J (2018) Alzheimer’s Association towards guidelines for dementia care practice: recommendations with emphasis on high-quality, person-centered care in long-term and community-based care settings. Alzheimers Dement 14:520–521
Gentier RJ, Verheijen BM, Zamboni M, Stroeken M, Hermes DJ, Küsters B, Van Leeuwen FW (2015) Localization of mutant ubiquitin in the brain of a transgenic mouse line with proteasomal inhibition and its validation at specific sites in Alzheimer’s disease. Front Neuroanat 9:26
Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, Zetterberg H (2014) Pathways to Alzheimer’s disease. J Intern Med 275(3):296–303
Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16(6):358
Huang C, Wahlund LO, Dierks T, Julin P, Winblad B, Jelic V (2000) Discrimination of Alzheimer’s disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol 111(11):1961–1967
Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Greenwald BS (2011) CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer’s disease. Mol Med 17(9–10):974
Loy CT, Schofield PR, Turner AM, Kwok JB (2014) Genetics of dementia. Lancet 383(9919):828–840
Mace NL, Rabins PV (2011) The 36-hour day: a family guide to caring for people who have Alzheimer disease, related dementias, and memory loss. JHU Press, Baltimore
Maslow K, Fortinsky RH (2018) Nonphysician care providers can help to increase detection of cognitive impairment and encourage diagnostic evaluation for dementia in community and residential care settings. The Gerontologist 58(suppl_1):S20–S31
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer’s disease. Nat Rev Dis Primers 15(1):15056
National Institute on Aging. Alzheimer’s disease Fact Sheet. 2016. Available from: https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet
Poil SS, De Haan W, van der Flier WM, Mansvelder HD, Scheltens P, Linkenkaer-Hansen K (2013) Integrative EEG biomarkers predict progression to Alzheimer’s disease at the MCI stage. Front Aging Neurosci 5:58
Putcha D, Brickhouse M, O’Keefe K, Sullivan C, Rentz D, Marshall G, Sperling R (2011) Hippocampal hyperactivation associated with cortical thinning in Alzheimer’s disease signature regions in non-demented elderly adults. J Neurosci 31(48):17680–17688
Quinodoz SA, Ollikainen N, Tabak B, Palla A, Schmidt JM, Detmar E, Aznauryan E (2017) Higher-order inter-chromosomal hubs shape 3-dimensional genome organization in the nucleus. bioRxiv. https://doi.org/10.1101/219683
Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63(11):1545–1550
Wang J, Zuo X, Dai Z, Xia M, Zhao Z, Zhao X, He Y (2013) Disrupted functional brain connectome in individuals at risk for Alzheimer’s disease. Biol Psychiatry 73(5):472–481
World Health Organization. WHO|Dementia. WHO [Internet]. World Health Organization. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs362/en/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Zubair, M. (2019). Genetics, Neuronal Pathways, and Electrophysiology of Alzheimer’s Disease. In: Ashraf, G., Alexiou, A. (eds) Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease. Springer, Singapore. https://doi.org/10.1007/978-981-13-9636-6_11
Download citation
DOI: https://doi.org/10.1007/978-981-13-9636-6_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-9635-9
Online ISBN: 978-981-13-9636-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)